United Therapeutics (UTHR) Surpasses Q4 Earnings and Revenue Estimates

Group 1 - United Therapeutics reported quarterly earnings of $6.19 per share, exceeding the Zacks Consensus Estimate of $6.10 per share, and up from $4.36 per share a year ago, representing an earnings surprise of 1.48% [1] - The company achieved revenues of $735.9 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 1.46%, and an increase from $614.7 million year-over-year [2] - Over the last four quarters, United Therapeutics has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Group 2 - The stock's immediate price movement will depend on management's commentary during the earnings call and future earnings expectations [3] - United Therapeutics shares have gained approximately 1.3% since the beginning of the year, matching the S&P 500's gain of 1.3% [3] - The current consensus EPS estimate for the upcoming quarter is $6.88 on revenues of $741.63 million, and for the current fiscal year, it is $27.49 on revenues of $3.14 billion [7] Group 3 - The estimate revisions trend for United Therapeutics is currently unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] - The Medical - Drugs industry, to which United Therapeutics belongs, is currently in the top 50% of Zacks industries, suggesting that stocks in this category tend to outperform those in the bottom 50% [8]